Table 2B.

The clinical trials of the combination of PD-1/PD-L1 blockade with other ICBs in cancer therapy

Targets	PD-1/PD-L1 blockade	Other ICB	Clinicaltrial no.	Phase	Tumor types	Findings	References
PD-L1×TIM-3	LY3300054	LY3321367	NCT02791334	Ib	Microsatellite instability-high/MMR-deficient tumors	Objective response occurred in 13 patients (32.5%) with monotherapy, 9 (45.0%) in the PD-1/PD-L1 inhibitor-naïve combination cohort, and 1 patient (4.5%) in the PD-1/PD-L1 inhibitor-resistant/refractory combination cohort.	200
PD-L1×TIM-3	LY300054	LY3321367	NCT03099109	Ia/b	Advanced solid Tumors	In the NSCLC monotherapy expansion cohort, anti-PD-1/L1 refractory patients (n= 23, ORR 0%, DCR 35%, PFS 1.9 months) versus anti-PD-1/L1 responders (n = 14, ORR 7%, DCR 50%, PFS 7.3 months). In combination expansion cohorts (n = 91), ORR and DCR were 4% and 42%.	201
PD-1×TIM-3	Spartalizumab	Sabatolimab	NCT02608268	I/Ib	Advanced solid Tumors	No response was seen with sabatolimab. 5 patients receiving combination treatment had PR (6%; lasting 12-27 months) in colorectal cancer (n = 2), NSCLC, malignant perianal melanoma, and SCLC.	202
PD-L1×TIM-3	LY3415244		NCT03752177	I	Advanced solid Tumors	One patient with PD-1 refractory NSCLC had a near partial response (29.6%).	203

ICB: immune checkpoint blockades; ORR: objective response rate; DCR: disease control rate; PFS: progression-free survival; NSCLC: non-small cell lung cancer; CAR-T: chimeric antigen receptor T-cell immunotherapy.